Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HER2-positive Breast Cancer × Blood Specimen Collection × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 117 Neoplasms 109 Lung Neoplasms 65 Colorectal Neoplasms 52 Carcinoma, Non-Small-Cell Lung 46 Prostatic Neoplasms 45 Pancreatic Neoplasms 33 Melanoma 33 Neoplastic Cells, Circulating 29 Ovarian Neoplasms 28 Head and Neck Neoplasms 26 Uterine Cervical Neoplasms 23 Multiple Myeloma 20 Colonic Neoplasms 20 Sarcoma 19 Glioma 19 Carcinoma, Hepatocellular 19 Neoplasm Metastasis 17 Leukemia, Myeloid, Acute 17 Lymphoma 15 Esophageal Neoplasms 15 Hematologic Neoplasms 14 Glioblastoma 14 Squamous Cell Carcinoma of Head and Neck 13 Leukemia 13 Endometrial Neoplasms 13 Myelodysplastic Syndromes 11 Kidney Neoplasms 11 Gastrointestinal Neoplasms 11 Carcinoma, Renal Cell 11

Interventions

Trastuzumab 33 pertuzumab 18 Docetaxel 16 pyrotinib 15 Paclitaxel 7 Capecitabine 6 tucatinib 5 Carboplatin 5 Ado-Trastuzumab Emtansine 4 trastuzumab deruxtecan 3 neratinib 3 atezolizumab 2 Protons 2 Fulvestrant 2 pegfilgrastim 1 palbociclib 1 margetuximab 1 liposomal doxorubicin 1 inavolisib 1 exemestane 1 envafolimab 1 dalpiciclib 1 Taxoids 1 Neoadjuvant Therapy 1 Metformin 1 Leuprolide 1 Letrozole 1 Isovaleryl-CoA Dehydrogenase 1 Injections 1 Hospital Information Systems 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04638725 2022-08-03

SIGHER

Institut de cancérologie Strasbourg Europe

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡